Recombinant Human CXCL12 Protein (68AA)

Beta LifeScience SKU/CAT #: BL-1802NP
BL-1802NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-1802NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human CXCL12 Protein (68AA)

Beta LifeScience SKU/CAT #: BL-1802NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human C-X-C Motif Chemokine 12 is produced by our E.coli expression system and the target gene encoding Lys22-Lys89 is expressed.
Accession P48061
Synonym Stromal Cell-Derived Factor 1; SDF-1; hSDF-1; C-X-C Motif Chemokine 12; Intercrine Reduced in Hepatomas; IRH; hIRH; Pre-B Cell Growth-Stimulating Factor; PBSF; CXCL12; SDF1; SDF1A; SDF1B
Gene Background Stromal Cell-Derived Factor-1 (SDF-1) is a chemokine member of the intercrine family. SDF1 is expressed as five isoforms that differ only in the C terminal tail. SDF1α and SDF1β are identical except for the four residues present in the C-terminus of SDF1β but absent from SDF1α. SDF1 isoforms interact with CXCR4 and CXCR7 receptors on the cell surface, and can also bind syndecan4. SDF1 is known to influence lymphopoiesis, regulate patterning and cell number of neural progenitors, and promote angiogenesis. It also enhances the survival of myeloid progenitor cells.
Molecular Mass 8 KDa
Apmol Mass 10 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Endotoxin Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Chemoattractant active on T-lymphocytes and monocytes but not neutrophils. Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. SDF-1-beta(3-72) and SDF-1-alpha(3-67) show a reduced chemotactic activity. Binding to cell surface proteoglycans seems to inhibit formation of SDF-1-alpha(3-67) and thus to preserve activity on local sites. Also binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for SDF-1. Binds to the allosteric site (site 2) of integrins and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1 in a CXCR4-independent manner. Acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. Stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1, a ligand for beta-2 integrins. SDF1A/CXCR4 signaling axis inhibits beta-2 integrin LFA-1 mediated adhesion of monocytes to ICAM-1 through LYN kinase. Inhibits CXCR4-mediated infection by T-cell line-adapted HIV-1. Plays a protective role after myocardial infarction. Induces down-regulation and internalization of ACKR3 expressed in various cells. Has several critical functions during embryonic development; required for B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation. Stimulates the proliferation of bone marrow-derived B-cell progenitors in the presence of IL7 as well as growth of stromal cell-dependent pre-B-cells.
Subcellular Location Secreted.
Protein Families Intercrine alpha (chemokine CxC) family
Database References
Tissue Specificity Isoform Alpha and isoform Beta are ubiquitously expressed, with highest levels detected in liver, pancreas and spleen. Isoform Gamma is mainly expressed in heart, with weak expression detected in several other tissues. Isoform Delta, isoform Epsilon and i

Gene Functions References

  1. CXCL12-positive cases exhibited shorter disease-free survival rates compared to CXCL12-negative cases. PMID: 30182340
  2. this study shows an essential role of CXCR7, together with CXCR4, in the control of normal and malignant hematopoietic cell migration and homing induced by CXCL12. PMID: 29433559
  3. CXCL12 rs1801157 is independently associated with Human papillomavirus infection and exerts influence in high grade intraepithelial lesions development PMID: 30227860
  4. silencing of CXCL12 had a protective effect on podocyte injury, which may be through inhibiting CXCL12/STAT3 signaling pathway. PMID: 29508174
  5. The CXCL12/SDF1 protein expression is a good prognostic biomarker in breast cancer. PMID: 29800557
  6. the CXCL12-CXCR4 axis promotes the migration, invasion, and EMT processes in B-CPAP cells, at least partly, by activating the NF-kappaB signaling pathway. PMID: 29316404
  7. Study shows that CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma (PTC). The study was the first to perform an reduced representation bisulfite sequencing analysis for PTC and suggested that CXCL12 may contribute to PTC development by methylation-mediated epigenetic regulation of gene expression. PMID: 28272462
  8. results demonstrate that non-oxidizable HMGB1 induce a sustained cardiac fibroblasts migration despite the redox state of the environment and by altering CXCL12/CXCR4 axis. This affects proper cardiac remodeling after an infarction. PMID: 28716707
  9. A basis for understanding how multiple elements in the sequence encoding the 3'UTR of the CXCL12 gene regulates its transcription and insights about diseases involving abnormal CXCL12alpha expression. PMID: 30266500
  10. High SDF-1 expression is associated with bladder cancer progression. PMID: 30015971
  11. High CXCL12 expression is associated with metastasis in colon cancer. PMID: 29305742
  12. MiR-125b functions as an important downstream mediator upon the activation of CXCL12/CXCR4 axis. PMID: 28176874
  13. CXCL12-related rs18011517 polymorphism was more frequent in non-Hodgkin lymphoma patients: it might be associated with non-Hodgkin lymphoma pathogenesis and outcome PMID: 30197351
  14. Data suggest that CXCL12 and its receptor CXCR4 are critical in maintaining homeostasis, specifically during hematopoiesis. Present clinical trials (especially in hematological tumors) are testing whether adding CXCR4 inhibitors to impair tumor dissemination will increase effectiveness of ongoing anti-cancer treatments. (CXCL12 = C-X-C motif chemokine ligand 12; CXCR4 = C-X-C motif chemokine receptor-4) [REVIEW] PMID: 29288743
  15. BCP-ALL cells actively migrate toward mesenchymal stromal cells (MSCs) in a CXCL12-dependent manner. PMID: 28619846
  16. Serum CXCR4 and CXCL12 levels increase significantly in septic neonates and they are valuable marker in diagnosis of neonatal sepsis. Serum concentrations of both chemokines represent promising novel biomarkers for neonatal sepsis. PMID: 28562124
  17. CXCL12 and CXCR4 polymorphisms may be risk factors for hepatocellular carcinoma (HCC), and they may be potential HCC markers. PMID: 29741398
  18. Stromal cell derived factor-1/C-X-C chemokine receptor type 4 axis induces human dental pulp stem cell migration through FAK/PI3K/Akt and GSK3beta/beta-catenin pathways. PMID: 28067275
  19. EGFR Over-expression and Mutations Leading to Biological Characteristics Changes of Human Lung Adenocarcinoma Cells through CXCR4/CXCL12 Signaling Pathway PMID: 30037369
  20. Serum CXCL12, but not CXCR4, Is Associated with Head and Neck Squamous Cell Carcinomas. PMID: 29693336
  21. The aim of the present study was to assess whether fibrosis markers, estrogen receptor (ER)alpha and the stromal derived factor (SDF)1/CXC chemokine receptor type 4 (CXCR4) axis are abnormally expressed in Intrauterine adhesions endometrium. PMID: 29568895
  22. HIV-1 infectors with SDF-1 3'A polymorphism have a higher chance of developing late AIDS. PMID: 30053458
  23. the SDF1/CXCR4 signaling pathway is involved in Lowintensity pulsed ultrasoundpromoted periodontal ligament stem cell migration. PMID: 29620151
  24. These results suggest that SDF1 (e.g. presented on proteoglycans) can rapidly activate integrins in an allosteric manner by binding to site 2 in the absence of CXCR4. The allosteric integrin activation by SDF1 is a novel target for drug discovery PMID: 29301984
  25. CXCL12 single nucleotide polymorphisms association with the risk of hypertension in Chinese Han population. PMID: 30180964
  26. These results suggest a key role for the CXCR4-CXCL12 chemokine axis in breast cancer progression and highlight the prognostic importance of this chemokine axis for breast cancer survival. PMID: 29516917
  27. serum SDF-1 is increased in and may be a potential useful marker for primary biliary cholangitis PMID: 29414663
  28. disruption of the CXCR4/CXCL12 axis by CXCR4 antagonist AMD3100 blocked the contribution of both cancer and stromal cells to the metastatic cascade in the liver. PMID: 29436696
  29. SDF-1 alpha overexpression in bone marrow-derived stromal stem cells promotes bone generation as indicated by osteogenesis and angiogenesis. PMID: 29758548
  30. These results suggest that SDF1, as an inflammatory cytokine, induces MMP expression in human endplate chondrocytes and that ECM remodeling in the degenerated cartilage endplate may be a favorable factor of endogenous stem cell homing into the nucleus pulposus for regeneration in vivo PMID: 29207021
  31. data demonstrate that: (i) hypoxia does not affect the capacity of EPCs to support the angiogenic process; (ii) the absence of either VEGF-A or SDF-1 from EPC-CM can be rescued by the presence of the other one, so that the overall angiogenic effects remain unchanged; and (iii) and the concomitant deletion of VEGF-A and SDF-1 from EPC-CM impairs its pro-angiogenic effect, both in vitro and in vivo. PMID: 27943613
  32. estrogen may promote the progression of ER-negative breast cancer by stimulating cancer-associated fibroblasts to secrete SDF-1alpha, which can recruit MDSCs to the tumor microenvironment to exert tumor-promoting effects PMID: 27996037
  33. Data support the importance of SDF-1 and CXCR4 expression for loco-regional control and overall survival in HNSCC after primary radiochemotherapy. PMID: 29061496
  34. Data (including data from studies in knockout mice) suggest that adipocyte autocrine function involving SDF1 regulates insulin resistance; SDF1 gene expression correlates with insulin-desensitized conditions in adipocytes but not other tissues (liver, skeletal muscle); adipocyte-specific ablation of Sdf1 enhances insulin sensitivity in adipose tissues and in whole body. PMID: 29581126
  35. Study reports that stromal cell-derived factor-1alpha elevated or therapeutically administered in ischemic wounded tissue can stimulate both local endothelial cells (EC) and bone marrow-derived endothelial progenitor cells (EPC) to express reciprocally E-selectin/ligand pairs and thereby enhance EPC-EC interactions. PMID: 27713493
  36. Authors produced recombinant CXCL12 and CXCL12(5-67) and evaluated their effect in murine adult NSCs migration and survival in vitro. We showed CXCL12(5-67) does not promote NSCs migration, but does induce cell death. PMID: 28623786
  37. a SDF-1/CXCR4-RhoA and RhoC-ROS-cytoskeleton pathway that regulates Jurkat cell migration in response to SDF-1. PMID: 28536953
  38. Expression upregulation of mir31 was also validated using GEO data sets. PMID: 27597234
  39. Differential expression of SDF-1 receptor CXCR4 in molecularly defined forms of inherited thrombocytopenias. PMID: 28032520
  40. A role for CXCl12 in bladder cancer [review] PMID: 29022185
  41. Intravenous administration of rhSDF-1alpha accelerates reendothelialization in the aneurysm neck after flow diverter implantation. PMID: 28159982
  42. These findings suggest a possibility that cells at the sites of MELF pattern had acquired increased invasiveness through the function of the CXCL14-CXCR4 and CXCL12-CXCR4 axes. PMID: 28277316
  43. study suggested that the SDF-1 rs1801157 polymorphism may serve as a risk factor for cancer development among Asians, especially an increased risk of urologic and lung cancers PMID: 27265091
  44. no significant association was found between SDF1 polymorphism and HIV susceptibility; a protective effect of SDF1 on AIDS progression and death was seen; in conclusion, SDF1 polymorphism exerts a moderate protective effect against AIDS disease deterioration in some specific populations PMID: 29420545
  45. Findings indicate that induction of EMT, increased migration and survival depend, in MCF-7 and H460 cells, on the release of FHC control on two pathways, namely the iron/ROS metabolism and CXCR4/CXCL12 axis. PMID: 28774348
  46. serum level is higher in preeclamptic women PMID: 28001450
  47. a defect of CXCL12 promoter histone acetylation may represent an additional process participating in CXCL12 expression extinction in colon cancer PMID: 28418886
  48. The findings indicated that SDF-1alpha/CXCR4 signaling pathway might be associated with the clinicopathological features and prognosis of patients with nasopharyngeal carcinoma. PMID: 28559386
  49. CXCL12-CXCR7 axis accelerates migration and invasion of pancreatic cancer cells through mTOR and Rho/ROCK pathways, and predicts poor prognosis of pancreatic cancer PMID: 27542220
  50. the role of CXCL12 in multiple sclerosis, with an emphasis on CXCL12 serum concentrations and its gene polymorphism at position +801 (Review) PMID: 27894110

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed